Knowledge base

1,274 claims across 14 domains

Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.

All 1,274 ai alignment 325 internet finance 263 health 211 space development 171 entertainment 131 grand strategy 101 energy 23 mechanisms 18 collective intelligence 14 manufacturing 5 robotics 5 critical systems 3 unknown 3 teleological economics 1

211 health claims

Kaiser Permanentes 80 year tripartite structure is the strongest precedent for purpose built payvidor exemptions because any structural separation bill that captures Kaiser faces 12.5 million members and Californias entire healthcare infrastructure

Kaiser Permanente is the original payvidor, operating since 1945. Its regulatory history is the most instructive precedent for how structural separation legislation would play out in practice.

anti payvidor legislation targets all insurer provider integration without distinguishing acquisition based arbitrage from purpose built care delivery

Two bills introduced in the 119th Congress would structurally prohibit the "payvidor" model -- insurers that also own or control care delivery:

medical care explains only 10 20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm

The claim that "90% of health outcomes are determined by non-clinical factors" has become a cornerstone of the value-based care and social determinants of health movements. The intellectual lineage traces through five decades of converging evidence:

healthcare AI regulation needs blank sheet redesign because the FDA drug and device model built for static products cannot govern continuously learning software

Bob Wachter argues that the current regulatory framework for healthcare AI is a "square peg and round hole problem." The FDA model was built for drugs that remain chemically identical forever and devices with fixed specifications. AI systems that learn, update, and adapt continuously break every ass

human in the loop clinical AI degrades to worse than AI alone because physicians both de skill from reliance and introduce errors when overriding correct outputs

The human-in-the-loop model -- where AI suggests and humans verify -- is the default safety architecture for clinical AI. But two lines of evidence suggest this model is fundamentally flawed rather than merely imperfect.

AI compresses drug discovery timelines by 30 40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics

AI-discovered drug candidates entering clinical trials have grown exponentially: 3 in 2016, 17 in 2020, 67 in 2023, an estimated 173 by 2026. AI compresses preclinical candidate development from 3-4 years to 13-18 months and achieves 80-90% Phase I success rates compared to 40-65% for traditional co

AI diagnostic triage achieves 97 percent sensitivity across 14 conditions making AI first screening viable for all imaging and pathology

The FDA has authorized 1,356 AI-enabled medical devices as of December 2025, up 8.5% from the prior report. Radiology dominates: 1,039 devices (77% of all authorizations), growing from 6 clearances in 2015 to 221 in 2023. In January 2026, Aidoc received clearance for healthcare's first comprehensive

AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review

Consumer wearables now generate continuous HR, HRV, SpO2, sleep staging, and activity data. Clinical workflows are designed for point-in-time measurements. A doctor knows how to act on a blood pressure reading but not on 30 days of continuous wrist-based blood pressure trend data. This gap is the ce

GLP 1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035

The GLP-1 receptor agonist market reached $63-70 billion in 2025, with Eli Lilly's Mounjaro/Zepbound generating over $36 billion and Novo Nordisk's semaglutide products contributing another $48.9 billion. The market is projected to reach $250-315 billion by 2035 at 12.8-17.5% CAGR.

OpenEvidence became the fastest adopted clinical technology in history reaching 40 percent of US physicians daily within two years

OpenEvidence is the breakout story in clinical AI. Developed by Harvard and MIT researchers, it operates across 10,000+ hospitals, handles 8.5 million clinical consultations per month, and was the first AI to score 100% on the USMLE. Strategic content partnerships with NEJM and JAMA ground its respo

Oura controls 80 percent of the smart ring market with patent defended form factor while a demographic pivot from fitness enthusiasts to wellness focused women drives 250 percent sales growth

Oura has achieved a rare combination in consumer hardware: dominant market share (80% of smart rings), accelerating revenue ($147M → $225M → $500M from 2022 to 2024), and a defensible form factor protected by patent litigation. The October 2025 $900M raise at $11B valuation (led by NEA, General Cata

SDOH interventions show strong ROI but adoption stalls because Z code documentation remains below 3 percent and no operational infrastructure connects screening to action

The evidence for SDOH intervention ROI is increasingly strong: food insecurity programs average 85% ROI (range 1-287%), housing programs average 50% ROI (range 5-224%), and one integrated SDOH care model showed 6.9:1 ROI with significantly fewer ED visits at 30 and 60 days. Social isolation alone co

WHOOP subscription only wearable model generates $260M revenue but trails Oura at half the revenue and a third the valuation because fitness first positioning limits the addressable wellness market

WHOOP's subscription-only model (device included with $199-359/year membership) is a genuine business model experiment in consumer health hardware. Subscriptions grew 20x since 2020 and revenue reached $260M in 2025. The screenless wrist strap, strain/recovery depth, and aspirational athlete endorse

ambient AI documentation reduces physician documentation burden by 73 percent but the relationship between automation and burnout is more complex than time savings alone

The ambient clinical documentation market reached $1.85B globally in 2024, growing at 28.7% annually to a projected $17.75B by 2033. Abridge leads with 100+ health systems including Johns Hopkins (6,700 clinicians), Mayo Clinic, and Memorial Sloan Kettering. Clinical results show 73% less after-hour

consumer CGMs are going mainstream as behavioral change tools not clinical diagnostics because real time glucose visibility changes food choices even without randomized trial evidence

The OTC CGM transition arrived in 2024-2025. Dexcom Stelo became the first OTC CGM (FDA-cleared March 2024), available on Amazon since May 2025 with 400,000+ app downloads. Abbott Lingo followed in June 2024, specifically targeting non-diabetics. Levels Health pairs prescription CGMs with coaching s

continuous health monitoring is converging on a multi layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware

The attractor state for health monitoring is not a single device but a multi-layer sensor architecture. Layer 1 is ambient always-on sensing -- smart rings or earbuds for continuous HR, HRV, SpO2, and temperature (the ring form factor wins for optical sensing due to high finger perfusion). Layer 2 i

four competing payer provider models are converging toward value based care with vertical integration dominant today but aligned partnership potentially more durable

The competitive landscape for value-based care is consolidating around four structural models:

gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment

As of early 2026, 46 cell and gene therapies have FDA approval, with prices concentrated in the $2-4M range: Casgevy ($2.2M for sickle cell), Lyfgenia ($3.1M), Zolgensma ($2.1M for SMA), Hemgenix ($3.5M for hemophilia B). These are all ex vivo therapies -- harvest cells, edit them, reinfuse -- requi

healthcare AI funding follows a winner take most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds

Global healthcare venture financing reached $60.4 billion in 2025, the strongest annual deployment in years, with digital health funding hitting $14.2 billion. But the headline number masks a deeply bifurcated market.

healthcare is a complex adaptive system requiring simple enabling rules not complicated management because standardized processes erode the clinical autonomy needed for value creation

Larsson, Clawson, and Howard argue that healthcare has become "a classic example of what system scientists term a complex adaptive system" -- and that the standard organizational response (standardized processes, KPIs, guidelines, compliance requirements) is precisely wrong. The compliance approach

medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials

Medical LLMs have reached and surpassed human benchmarks: OpenEvidence scored 100% on USMLE, Med-PaLM 2 achieved 86.5% on MedQA, and GPT-4 outperformed ED resident physicians in diagnostic accuracy for structured internal medicine cases. But a UVA/Stanford/Harvard randomized trial found that physici

personalized mRNA cancer vaccines show sustained 49 percent reduction in melanoma recurrence after five years representing a genuinely novel therapeutic paradigm

The Moderna/Merck partnership on intismeran (mRNA-4157/V940) represents the most advanced non-COVID mRNA therapeutic and a genuinely novel approach to cancer treatment. The vaccine is manufactured individually for each patient: tumor DNA is sequenced, up to 34 neoantigens are selected, and personali

prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without the pricing power that justifies it for near zero marginal cost software

The prescription digital therapeutics (PDT) model attempted to replicate pharmaceutical business logic -- FDA clearance followed by insurance reimbursement -- without pharmaceutical economics. All three flagship companies collapsed:

social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem

In May 2023, US Surgeon General Vivek Murthy released the landmark advisory "Our Epidemic of Loneliness and Isolation," establishing loneliness as a public health crisis. The data: loneliness carries mortality risk equivalent to smoking 15 cigarettes per day, social isolation among older adults acco

the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification

The FDA's January 2026 guidance update established a critical distinction: non-invasive wearables estimating health metrics can claim general wellness status if they avoid disease/diagnostic/clinical management claims. A fitness tracker can detect "patterns and events that warrant a closer look" --